Aytu Biopharma, Inc.
AYTU
$2.19
$0.063.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.38% | 1.84% | -19.04% | -31.79% | -34.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.38% | 1.84% | -19.04% | -31.79% | -34.46% |
| Cost of Revenue | 29.64% | 27.42% | -22.40% | -44.57% | -55.63% |
| Gross Profit | -10.35% | -6.57% | -17.57% | -25.05% | -22.12% |
| SG&A Expenses | -6.65% | -8.93% | -15.90% | -28.93% | -37.83% |
| Depreciation & Amortization | -12.88% | 0.00% | -6.92% | -13.03% | -18.49% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.22% | -1.20% | -17.12% | -32.45% | -42.57% |
| Operating Income | -8.32% | 349.03% | -58.88% | 46.76% | 111.14% |
| Income Before Tax | -843.71% | -32.44% | 130.70% | 84.59% | 94.09% |
| Income Tax Expenses | -98.74% | -79.60% | -35.36% | 90.26% | -- |
| Earnings from Continuing Operations | -236.62% | -13.27% | 120.00% | 76.33% | 83.40% |
| Earnings from Discontinued Operations | 110.41% | 118.65% | 67.34% | 10.23% | -254.87% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.14% | 14.40% | 111.98% | 70.87% | 74.46% |
| EBIT | -8.32% | 349.03% | -58.88% | 46.76% | 111.14% |
| EBITDA | -20.93% | 7.28% | -35.71% | -5.67% | 335.47% |
| EPS Basic | -69.28% | 33.83% | 107.62% | 75.98% | 81.48% |
| Normalized Basic EPS | -254.33% | 73.33% | 194.74% | 111.66% | 107.36% |
| EPS Diluted | -98.15% | -9.14% | 60.87% | 56.51% | 74.99% |
| Normalized Diluted EPS | -493.35% | 47.49% | 167.93% | 105.33% | 104.72% |
| Average Basic Shares Outstanding | 25.33% | 13.42% | 15.85% | 23.76% | 38.12% |
| Average Diluted Shares Outstanding | 66.69% | 47.07% | 51.90% | 52.29% | 56.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |